ACL Implements New In-House Test Next-Generation Sequencing (NGS) for Myeloid Malignancies (LAB11222)

September 21, 2022

Effective Wednesday, September 21, 2022, ACL Laboratories will implement a new in-house test, Next-Generation Sequencing (NGS) for Myeloid Malignancies Panel by NGS (Test Order Code LAB11222).

Clinical indication:
ACL NGS Myeloid assay based on Thermo Fisher NGS Oncomine™ Myeloid reagents - is a comprehensive, targeted NGS assay, which interrogates all relevant DNA mutations and fusion transcripts associated with myeloid disorders in a single NGS run.

ACL NGS Myeloid 74 gene panel comprises 40 key DNA target genes and 29 fusion driver genes to cover all the major myeloid disorders associated with: Chronic myelomonocytic leukemia (**CMML**), Juvenile myelomonocytic leukemia (**JMML**), Acute myeloid leukemia (**AML**), Myeloid dysplastic syndrome (**MDS**), Chronic myeloid leukemia (**CML**), Myeloproliferative neoplasms (**MPN**).

Test Method: This test will be performed by ACL Laboratories using Next Generation Sequencing.

Preferred Specimen:
- Blood: One pink EDTA 6.0 mL or two lavender EDTA 3.0 mL (also acceptable: Green sodium or lithium heparin 3.0 mL) or
- Bone marrow: Lavender 1.0 mL in EDTA or Green sodium heparin or lithium heparin 1 mL) or
- WBC in RPMI solution 3 mL

Transport: Refrigerated

Performed: Weekdays

Performing Sites: Illinois Central Laboratory – Molecular Pathology

Reporting Time: Final within 14 days

This new ACL assay has the performance characteristics comparable to the current reference laboratory assays, ARUP and Neogenomics, and will detect the same relevant DNA mutation variants and additionally provide results for RNA fusions driver variants.

Current Next-Generation Sequencing for Acute Myeloid Leukemia send out test **LAB10597** will be discontinued effective Wednesday, September 21st , 2022.

If you have any questions, please contact:
ACL Molecular Pathology Laboratory at Rosemont (ph. 847-349-7182), or
Michael Mihalov, MD - Medical Director (ph. 847-349-7401), or
Lech Mazur, MS - Technical Director (ph. 847-349-7185)